Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in the Netherlands

Journal of Medical Economics

Volumn 18, Issue 1, 2015, Pages 76-87

  Henry, Thea L ^a   De Brouwer, Bonnie F E ^b   Van Keep, Marjolijn M L ^a   Blankestijn, Peter J ^c   Bots, Michiel L ^c   Koffijberg, Hendrik ^c  

^a BRESMED   (United Kingdom)

^b MEDTRONIC Trading NL   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cardiovascular disease; Cost effectiveness; Prevention; Renal sympathetic denervation; Resistant hypertension

Indexed keywords

AMLODIPINE; HYDROCHLOROTHIAZIDE; PERINDOPRIL; SIMVASTATIN;

ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; END STAGE RENAL DISEASE; FEMALE; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH STATUS; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; COST BENEFIT ANALYSIS; DENERVATION; ECONOMICS; HYPERTENSION; INNERVATION; KIDNEY; MIDDLE AGED; PROBABILITY; PROCEDURES; STATISTICAL MODEL;

AGED; COST-BENEFIT ANALYSIS; DENERVATION; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMETRIC; NETHERLANDS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84918784608     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.978453     Document Type: Article

References (60)

1. He J, Whelton PK. Epidemiology and prevention of hypertension. Med Clin North Am 1997;81:1077-97
2. Whelton PK. Epidemiology of hypertension. Lancet 1994;344:101-6
3. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
4. Ezzati M, Lopez AD, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60
5. Sarafidis PA, Bakris GL. Resistant hypertension an overview of evaluation and treatment. J Am Coll Cardiol 2008;52:1749-57
6. Perkovic V, Huxley R, Wu Y, et al. The burden of blood pressurerelated disease: a neglected priority for global health. Hypertension 2007;50:991-7
7. Lawes CM, Vander Hoorn S, Rodgers A, et al. Global burden of bloodpressure- related disease, 2001. Lancet 2008;371:1513-18
8. Carrington MJ, Jennings GL, Stewart S. Pattern of blood pressure in Australian adults: results from a national blood pressure screening day of 13,825 adults. Int J Cardiol 2010;145:461-7
9. Pimenta E, Calhoun DA. Resistant hypertension: incidence, prevalence, and prognosis. Circulation 2012;125:1594-6
10. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012;125:1635-42
11. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373:1275-81
12. Symplicity HTN Investigators, Esler MD, Krum H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376:1903-9
13. Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 2014;383:622-9
14. Dorenkamp M, Bonaventura K, Leber AW, et al. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension. Eur Heart J 2013;34:451-61
15. Geisler BP, Egan BM, Cohen JT, et al. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol 2012;60:1271-7
16. Gladwell G, Henry T, Cook M, et al. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK. J App Health Econ Health Policy 2014. [Epub ahead of print]
17. Rutten FFH, Rodenburg-van Dieten HEM, Herings RMC, et al. Guidelines for pharmacoeconomic research, updated version College voor Zorgverzekeringen. Diemen, NL: College voor Zorgverzekeringen; 2006. http://www.cvz.nl/pakket/werkwijzepakketbeheer/beoordelinggeneesmiddelen/farmaco-economischonderzoek. Accessed October 23, 2013
18. Voss R, Cullen P, Schulte H, et al. Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Munster Study (PROCAM) using neural networks. Int J Epidemiol 2002;31:1253-62; discussion 1262-4
19. European Renal Association (ERA)-European Dialysis and Transplant Association (EDTA) Registry. ERA-EDTA Registry Annual Report 2010. Amsterdam, The Netherlands: Academic Medical Center, Department of Medical Informatics, 2012
20. Sterfte; geslacht, leeftijd (op 31 december) en burgerlijke staat. Den Haag/Heerlen, NL: Centraal Bureau voor de Statistiek, 2012. http://statline.cbs.nl/StatWeb/publication/default.aspx?DM=SLNL&PA=37530NED&D1=3%2c5&D2=1-100&D3= 0&D4=l&VW=T. Accessed August 21, 2013
21. Consumentenprijzen; inflatie vanaf 1963. Den Haag/Heerlen, NL: Centraal Bureau voor de Statistiek, 2013. http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA=70936 NED&D1=0&D2=467,480,493,506,519,532,545,558,571,584,597,610, 623,636,649,662&VW=T. Accessed October 23, 2013
22. Nederlandse Zorgautoriteit. Marktscan en beleidsbrief Extramurale Farmaceutische zorg: Beeld van de markt met vrije prijzen Nederlandse Zorgautoriteit. Utrecht, NL, 2013. http://www.nza.nl/104107/105773/742312/Marktscan-Extramurale-farmaceutische-zorg.pdf. Accessed March 14, 2014
23. Hakkaart-van Roijen L, Tan S, Bouwmans C. Handleiding voor kostenonderzoek. Diemen, NL: College voor Zorgverzekeringen, 2010. http://www.cvz.nl/binaries/content/documents/zinl-www/documenten/publicaties/overige-publicaties/1007-handleiding-voor-kostenonderzoek/1007-handleiding-voorkostenonderzoek/Handleidingvoorkostenonderzoek.pdf. Accessed October 23, 2013
24. Banga JD, van Dijk JL, van Dis I, Giepmans L et al. Cardiovasculair risicomanagement (Tweede herziening). Huisarts Wet 2012;55:14-28
25. Eefting F, Nathoe H, van Dijk D, et al. Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. Circulation 2003;108:2870-6
26. Kind P, Hardman G, Macran S. UK population norms for EQ-5D. Discussion paper 172. York, UK: Centre for Health Economics, University of York, 1999. http://www.york.ac.uk/media/che/documents/papers/discussionpapers/CHE%20Discussion%20Paper%20172.pdf. Accessed August 21, 2013
27. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370:1393-401
28. van Buschbach JJ, Delwel GO. Het pakketprincipe kosteneffectiviteit achtergrondstudie ten behoeve van de 'appraisal' fase in pakketbeheer. Diemen, NL: College voor Zorgverzekeringen, 2013. http://www.cvz.nl/pakket/werkwijzepakketbeheer/proceduresenmethodiek. Accessed October 23, 2013
29. Brindle P, Emberson J, Lampe F, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. Br Med J 2003;327:1267-1272
30. Banach M, Nikfar S, Rahimi R, et al. The effects of statins on blood pressure in normotensive or hypertensive subjects-a meta-analysis of randomized controlled trials. Int J Cardiol 2013;168:2816-24
31. Strazzullo P, Kerry SM, Barbato A, et al. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials. Hypertension 2007;49:792-8
32. Golomb BA, Dimsdale JE, White HL, et al. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial. Arch Intern Med 2008;168:721-7
33. Verloop WL, Vink EE, Voskuil M, et al. Eligibility for percutaneous renal denervation: the importance of a systematic screening. J Hypertens 2013;31:1662-8
34. Wolf PA, D'Agostino RB, Belanger AJ, et al. Probability of stroke: a risk profile from the Framingham Study. Stroke 1991;22:312-18
35. D'Agostino RB, Wolf PA, Belanger AJ, et al. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 1994;25:40-3
36. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000;139:272-81
37. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47
38. Kannel WB, D'Agostino RB, Silbershatz H, et al. Profile for estimating risk of heart failure. Arch Intern Med 1999;159:1197-204
39. Velagaleti RS, Pencina MJ, Murabito JM, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation 2008;118:2057-62
40. Hsu CY, Vittinghoff E, Lin F, et al. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med 2004;141:95-101
41. Hsu CY, Iribarren C, McCulloch CE, et al. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009;169:342-50
42. Saposnik G, Hill MD, O'Donnell M, et al. Variables associated with 7-day, 30-day, and 1-year fatality after ischemic stroke. Stroke 2008;39:2318-24
43. Rogers WJ, Frederick PD, Stoehr E, et al. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008;156:1026-34
44. Flack JM, Neaton J, Grimm Jr R, et al. Blood pressure and mortality among men with prior myocardial infarction. Multiple Risk Factor Intervention Trial Research Group. Circulation 1995;92:2437-45
45. Barakat K, Wilkinson P, Deaner A, et al. How should age affect management of acute myocardial infarction? A prospective cohort study. Lancet 1999;353:955-9
46. Pocock SJ, Wang D, Pfeffer MA, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006;27:65-75
47. Medicijnkosten. Zorginstituut Nederland. Diemen, NL: College voor Zorgverzekeringen, 2014. http://www.medicijnkosten.nl/. Accessed August 29, 2013
48. Rutten FH, Bohnen AM, Schreuder BP, Pupping MDA, Bouma M. NHG-standaard Stabiele angina pectoris (Tweede herziening). Huisarts Wet 2005:47:83-95
49. Adarkwah CC, Gandjour A, Akkerman M, et al. Cost-effectiveness of angiotensin- converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands-a Markov model. PLoS One 2011;6:e26139
50. Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005;68:2801-8
51. DBC Zorgproducten tariefapplicatie. Nederlandse Zorgautoriteit. Utrecht, NL: Nederlandse Zorgautoriteit, 2013. http://dbc-zorgproducten-tarieven.nza.nl/nzaZpTarief/ZoekfunctieDbc.aspx. Accessed October 23, 2013
52. Comin-Colet J, Lainscak M, Dickstein K, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J 2013;34:30-8
53. Hoes AW, Voors AA, Rutten FH, van Lieshout J, Janssen PGH, Walma EP. NHG-standaard Hartfalen (Tweede herziening). Huisarts Wet 2010: 53:368-389
54. Ward S, Myfanwy LJ, Abdullah P, et al. Technology assessment report commissioned by the HTS Programme on behalf of The National Institute for Clinical Excellence: Statins for the prevention of Coronary Events. Sheffield, UK: School of Health and Related Research, University of Sheffield, 2005
55. NICE. Hypertension: management of hypertension in adults in primary care (CG34). London, UK: National Institute for Health and Clinical Excellence (NICE), 2006. http://www.nice.org.uk/guidance/index.jsp?action=byID&r= true&o=10986. Accessed December 2012
56. Soekhlal RR, Burgers LT, Redekop WK, et al. Treatment costs of acute myocardial infarction in the Netherlands. Neth Heart J 2013;21:230-5
57. Goodacre S, Nicholl J, Dixon S, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. Br Med J 2004;328:254
58. Greving JP, Visseren FL, de Wit GA, et al. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. Br Med J 2011;342:d1672
59. Amemiya S, Takao H. Computed tomographic coronary angiography for diagnosing stable coronary artery disease: a cost-utility and cost-effectiveness analysis. Circ J 2009;73:1263-70
60. Darlington AS, Dippel DW, Ribbers GM, et al. Coping strategies as determinants of quality of life in stroke patients: a longitudinal study. Cerebrovasc Dis 2007;23:401-7